Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00679211 |
This is a Phase II, multi-institutional, single-arm, open-label study of T-DM1 administered to patients with HER2-positive MBC. A total of approximately 100 patients are to be enrolled and treated, and the total enrollment period is expected to span approximately 50 weeks. The follow-up period required for assessment of response and duration of response will be reached approximately 26 weeks after the last patient is enrolled in the study.
Condition | Intervention | Phase |
---|---|---|
Metastatic Breast Cancer |
Drug: trastuzumab-MCC-DM1 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Factorial Assignment |
Official Title: | A Phase II, Single-Arm, Open-Label Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer |
Estimated Enrollment: | 100 |
Study Start Date: | July 2008 |
Estimated Primary Completion Date: | February 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: trastuzumab-MCC-DM1
Intravenous repeating dose
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Genentech Trial Information Support Line | 888-662-6728 |
Study Director: | Sam Agresta, M.D., M.P.H. | Genentech |
Responsible Party: | Genentech, Inc. ( Clinical Trials Posting Group ) |
Study ID Numbers: | TDM4374g |
Study First Received: | May 14, 2008 |
Last Updated: | January 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00679211 |
Health Authority: | United States: Food and Drug Administration |
HER2-positive breast cancer HER2 MBC |
Myotonia atrophica Skin Diseases Myotonic Dystrophy Trastuzumab |
Breast Neoplasms Dystrophia myotonica 1 Breast Diseases |
Neoplasms Neoplasms by Site Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |